home / stock / lvtx / lvtx quote
Last: | $2.74 |
---|---|
Change Percent: | 0.0% |
Open: | $2.98 |
Close: | $2.74 |
High: | $3.01 |
Low: | $2.73 |
Volume: | 153,573 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.74 | $2.98 | $2.74 | $3.01 | $2.73 | 153,573 | 04-24-2024 |
$2.98 | $2.93 | $2.98 | $3.15 | $2.9001 | 106,390 | 04-23-2024 |
$2.85 | $2.72 | $2.85 | $2.93 | $2.69 | 87,769 | 04-22-2024 |
$2.71 | $2.8 | $2.71 | $2.82 | $2.6391 | 133,347 | 04-19-2024 |
$2.83 | $2.94 | $2.83 | $3.02 | $2.8135 | 103,713 | 04-18-2024 |
$2.94 | $2.88 | $2.94 | $3.0764 | $2.88 | 59,589 | 04-17-2024 |
$2.89 | $2.89 | $2.89 | $3.07 | $2.88 | 73,208 | 04-16-2024 |
$2.93 | $3.12 | $2.93 | $3.24 | $2.88 | 132,610 | 04-15-2024 |
$3.13 | $3.32 | $3.13 | $3.39 | $3.05 | 151,713 | 04-12-2024 |
$3.34 | $3.04 | $3.34 | $3.57 | $3.03 | 525,407 | 04-11-2024 |
$3.04 | $2.75 | $3.04 | $3.16 | $2.51 | 478,622 | 04-10-2024 |
$2.71 | $2.97 | $2.71 | $2.97 | $2.69 | 313,499 | 04-09-2024 |
$2.95 | $3.02 | $2.95 | $3.07 | $2.94 | 97,622 | 04-08-2024 |
$3.05 | $2.95 | $3.05 | $3.11 | $2.8254 | 172,319 | 04-05-2024 |
$2.87 | $3.1 | $2.87 | $3.23 | $2.8201 | 301,443 | 04-04-2024 |
$3.11 | $3.07 | $3.11 | $3.32 | $3.01 | 271,489 | 04-03-2024 |
$3.12 | $3.46 | $3.12 | $3.49 | $2.9 | 530,853 | 04-02-2024 |
$3.37 | $3.27 | $3.37 | $3.45 | $3.24 | 248,024 | 04-01-2024 |
$3.33 | $3.92 | $3.33 | $3.9298 | $3.31 | 490,993 | 03-29-2024 |
$3.33 | $3.92 | $3.33 | $3.9298 | $3.31 | 490,993 | 03-28-2024 |
News, Short Squeeze, Breakout and More Instantly...
LAVA Therapeutics N.V. Company Name:
LVTX Stock Symbol:
NASDAQ Market:
2024-03-20 10:20:00 ET March 20, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech/Life Sciences sector. The newest biotech companies are involved in immuno-oncology, ...
LAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2 2024 In March 2024, Pfizer paid LAVA $7 million for achieving a clinical milestone for EGFRd2 (PF-08046052/formerly LAVA-1223) LAVA 1266 tracking to Q2 2024 IND submission...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 61.6% to $0.143 on volume of 387,468,585 shares Fisker Inc. Class A (FSR) fell 8.5% to $0.4415 on volume of 205,557,321 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 3.0% to $3.22 on vol...